Find Omalizumab manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

Listed Suppliers

read-more
read-more

01

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Omalizumab

About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.
LGM Pharma CB

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content

Omalizumab

About the Company : ​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...

​Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry.
Shanghai Minbiotech CB

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMesochem is focused on incessant innovation along with the R&D of new APIs.

Flag China
Digital Content Digital Content

Omalizumab

About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...

Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine chemicals and fundamental chemical materials. It has an efficient research and development team. Beijing Mesochem provides its customers customized development, craft optimization, contract customization and outsourcing services. The company has a well-established industrial base in Weinan, Shanxi Province. The production base features a 20,000 ㎡ plant with a production capacity of over 8,000 MT per year.
Mesochem Company Banner

04

BIOHK2025
Not Confirmed
arrow
arrow
BIOHK2025
Not Confirmed

Omalizumab

About the Company : Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We...

Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We started business in early 2010, producing and providing products for both human and veterinary health at home and abroad. Conscientia Industrial makes regular productions and also provides custom synthesis, contract manufacturing services. We have series of products, such as Hormones, Prostaglandins, Peptides, Anti-cancer, Anti-tumor, Anti-virus, Anti-diabetic APIs and their related intermediates, impurities, chemicals.
blank

05

BIOHK2025
Not Confirmed
arrow
arrow
BIOHK2025
Not Confirmed

Omalizumab

About the Company : Hebei Huarong Pharmaceutical Co., Ltd (HRPC) is jointly invested by CSPC and Taoyuan Group, CSPC send people for administration. The company was established in 1993, which is mainl...

Hebei Huarong Pharmaceutical Co., Ltd (HRPC) is jointly invested by CSPC and Taoyuan Group, CSPC send people for administration. The company was established in 1993, which is mainly engaged in manufacturing and marketing Vitamin B12, feed additive and acarbose. After nearly 20 years of development, HRPC has developed into an influential and professional producer. HRPC has full range of products and superb quality, more than 80% of the products export to abroad. HRPC is credited as the export-oriented and technique-advanced enterprise in Hebei province.
blank

06

BIOHK2025
Not Confirmed
arrow
arrow
BIOHK2025
Not Confirmed

Omalizumab

About the Company : Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are pro...

Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are proud to be the leading company in the Asia-Pacific region that successfully researched and developed Active Pharmaceutical Ingredients (APIs) and specific therapeutic products on the foundation of advanced recombinant DNA/protein technology.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

CELLTRION INC

South Korea
BIOHK2025
Not Confirmed
arrow

CELLTRION INC

South Korea
arrow
BIOHK2025
Not Confirmed

OMALIZUMAB-IGEC

Brand Name : OMLYCLO

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 75MG/0.5ML

Approval Date :

Application Number : 761399

RX/OTC/DISCN :

RLD :

TE Code :

blank

02

CELLTRION INC

South Korea
BIOHK2025
Not Confirmed
arrow

CELLTRION INC

South Korea
arrow
BIOHK2025
Not Confirmed

OMALIZUMAB-IGEC

Brand Name : OMLYCLO

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 150MG/ML

Approval Date :

Application Number : 761399

RX/OTC/DISCN :

RLD :

TE Code :

blank

03

GENENTECH

U.S.A
BIOHK2025
Not Confirmed
arrow

GENENTECH

U.S.A
arrow
BIOHK2025
Not Confirmed

OMALIZUMAB

Brand Name : XOLAIR

Dosage Form : VIAL

Dosage Strength : 150MG/VIAL

Approval Date :

Application Number : 103976

RX/OTC/DISCN :

RLD :

TE Code :

blank

04

GENENTECH

U.S.A
BIOHK2025
Not Confirmed
arrow

GENENTECH

U.S.A
arrow
BIOHK2025
Not Confirmed

OMALIZUMAB

Brand Name : XOLAIR

Dosage Form : SYRINGE

Dosage Strength : 75MG/0.5ML

Approval Date :

Application Number : 103976

RX/OTC/DISCN :

RLD :

TE Code :

blank

05

GENENTECH

U.S.A
BIOHK2025
Not Confirmed
arrow

GENENTECH

U.S.A
arrow
BIOHK2025
Not Confirmed

OMALIZUMAB

Brand Name : XOLAIR

Dosage Form : SYRINGE

Dosage Strength : 150MG/ML

Approval Date :

Application Number : 103976

RX/OTC/DISCN :

RLD :

TE Code :

blank

06

GENENTECH

U.S.A
BIOHK2025
Not Confirmed
arrow

GENENTECH

U.S.A
arrow
BIOHK2025
Not Confirmed

OMALIZUMAB

Brand Name : XOLAIR

Dosage Form : SYRINGE

Dosage Strength : 300MG/2ML

Approval Date :

Application Number : 103976

RX/OTC/DISCN :

RLD :

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
World Drug Safety EU
Not Confirmed
arrow
World Drug Safety EU
Not Confirmed

Company : Genentech, Inc.

Omalizumab

Drug Cost (USD) : 254,056,609

Year : 2023

Prescribers : 9161

Prescriptions : 79113

blank

02

arrow
World Drug Safety EU
Not Confirmed
arrow
World Drug Safety EU
Not Confirmed

Company : Genentech, Inc.

Omalizumab

Drug Cost (USD) : 208,230,097

Year : 2022

Prescribers : 8052

Prescriptions : 68699

blank

03

arrow
World Drug Safety EU
Not Confirmed
arrow
World Drug Safety EU
Not Confirmed

Company : Genentech, Inc.

Omalizumab

Drug Cost (USD) : 161,212,650

Year : 2021

Prescribers : 6736

Prescriptions : 54013

blank

04

arrow
World Drug Safety EU
Not Confirmed
arrow
World Drug Safety EU
Not Confirmed

Company : Genentech, Inc.

Omalizumab

Drug Cost (USD) : 150,601,321

Year : 2020

Prescribers : 6456

Prescriptions : 49179

blank

05

arrow
World Drug Safety EU
Not Confirmed
arrow
World Drug Safety EU
Not Confirmed

Company : Genentech, Inc.

Omalizumab

Drug Cost (USD) : 147,919,046

Year : 2019

Prescribers : 6515

Prescriptions : 45771

blank

06

arrow
World Drug Safety EU
Not Confirmed
arrow
World Drug Safety EU
Not Confirmed

Company : Genentech, Inc.

Omalizumab

Drug Cost (USD) : 138,941,935

Year : 2018

Prescribers : 6137

Prescriptions : 40026

blank

07

arrow
World Drug Safety EU
Not Confirmed
arrow
World Drug Safety EU
Not Confirmed

Company : Genentech, Inc.

Omalizumab

Drug Cost (USD) : 120,407,241

Year : 2017

Prescribers : 5423

Prescriptions : 34919

blank

08

arrow
World Drug Safety EU
Not Confirmed
arrow
World Drug Safety EU
Not Confirmed

Company : Genentech, Inc.

Omalizumab

Drug Cost (USD) : 79,002,423

Year : 2016

Prescribers : 3844

Prescriptions : 23913

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Xolair

Omalizumab

arrow
World Drug Safety EU
Not Confirmed

Brand Name : Xolair

Switzerland
arrow
World Drug Safety EU
Not Confirmed

Omalizumab

Main Therapeutic Indication : Immunology

Currency : USD

2019 Revenue in Millions : 2,028

2018 Revenue in Millions : 1,969

Growth (%) : 3

blank

02

Brand Name : Xolair

Omalizumab

arrow
World Drug Safety EU
Not Confirmed

Brand Name : Xolair

Switzerland
arrow
World Drug Safety EU
Not Confirmed

Omalizumab

Main Therapeutic Indication : Immunology

Currency : USD

2020 Revenue in Millions : 2,121

2019 Revenue in Millions : 2,194

Growth (%) : -3

blank

03

Brand Name : Xolair

Omalizumab

arrow
World Drug Safety EU
Not Confirmed

Brand Name : Xolair

Switzerland
arrow
World Drug Safety EU
Not Confirmed

Omalizumab

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 1,251

2019 Revenue in Millions : 1,173

Growth (%) : 7

blank

04

Brand Name : Xolair

Omalizumab

arrow
World Drug Safety EU
Not Confirmed

Brand Name : Xolair

Switzerland
arrow
World Drug Safety EU
Not Confirmed

Omalizumab

Main Therapeutic Indication : Immunology

Currency : USD

2021 Revenue in Millions : 2,090

2020 Revenue in Millions : 2,018

Growth (%) : 2

blank

05

Brand Name : Xolair

Omalizumab

arrow
World Drug Safety EU
Not Confirmed

Brand Name : Xolair

Switzerland
arrow
World Drug Safety EU
Not Confirmed

Omalizumab

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 1,428

2020 Revenue in Millions : 1,251

Growth (%) : 14

blank

06

Brand Name : Xolair

Omalizumab

arrow
World Drug Safety EU
Not Confirmed

Brand Name : Xolair

Switzerland
arrow
World Drug Safety EU
Not Confirmed

Omalizumab

Main Therapeutic Indication : Immunology

Currency : USD

2022 Revenue in Millions : 1,365

2021 Revenue in Millions : 1,428

Growth (%) : -4

blank

07

Brand Name : Xolair

Omalizumab

arrow
World Drug Safety EU
Not Confirmed

Brand Name : Xolair

Switzerland
arrow
World Drug Safety EU
Not Confirmed

Omalizumab

Main Therapeutic Indication : Immunology

Currency : USD

2022 Revenue in Millions : 2,414

2021 Revenue in Millions : 2,090

Growth (%) : 15

blank

08

Brand Name : Xolair

Omalizumab

arrow
World Drug Safety EU
Not Confirmed

Brand Name : Xolair

Switzerland
arrow
World Drug Safety EU
Not Confirmed

Omalizumab

Main Therapeutic Indication : Immunology

Currency : USD

2023 Revenue in Millions : 2,525

2022 Revenue in Millions : 2,414

Growth (%) : -1

blank

09

Brand Name : Xolair

Omalizumab

arrow
World Drug Safety EU
Not Confirmed

Brand Name : Xolair

Switzerland
arrow
World Drug Safety EU
Not Confirmed

Omalizumab

Main Therapeutic Indication : Immunology

Currency : USD

2023 Revenue in Millions : 1,463

2022 Revenue in Millions : 1,365

Growth (%) : 7

blank

10

Brand Name : Xolair

Omalizumab

arrow
World Drug Safety EU
Not Confirmed

Brand Name : Xolair

Switzerland
arrow
World Drug Safety EU
Not Confirmed

Omalizumab

Main Therapeutic Indication : Immunology

Currency : USD

2024 Revenue in Millions : 1,643

2023 Revenue in Millions : 1,463

Growth (%) : 12

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty